Zolaren Suspension 1% contains Brinzolamide, a carbonic anhydrase inhibitor, and is indicated for the management of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Elevated IOP is a major risk factor for optic nerve damage in glaucoma, which can lead to irreversible vision loss. Zolaren 1% helps reduce IOP by decreasing the production of aqueous humor in the eye, thereby protecting the optic nerve and maintaining visual function.

This suspension is particularly useful:

• In patients who are intolerant to or inadequately controlled with other glaucoma medications

• As monotherapy or in combination with other anti-glaucoma agents, such as prostaglandin analogs or beta-blockers, for additive IOP-lowering effects

By effectively lowering intraocular pressure, Zolaren Suspension helps prevent progression of glaucomatous damage and vision deterioration.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Pharmacology

Brinzolamide, the active ingredient in Zolaren, is a selective inhibitor of carbonic anhydrase II, an enzyme involved in the production of aqueous humor in the ciliary body of the eye. By inhibiting carbonic anhydrase, Brinzolamide reduces the formation of bicarbonate ions, which in turn decreases sodium and fluid transport into the anterior chamber. This leads to reduced intraocular pressure.

The drug acts locally in the eye, and systemic absorption is minimal, reducing the risk of systemic side effects. Peak IOP reduction is typically observed within 2–3 hours of administration, and the effect is maintained with consistent dosing.

Dosage & Administration

• The recommended dose of Zolaren Suspension 1% is one drop in the affected eye(s) two to three times daily.

• In patients using multiple topical ophthalmic medications, the medications should be administered at least 5–10 minutes apart to avoid washout and ensure optimal efficacy.

• Patients should be advised to gently close the eyes and apply slight pressure to the inner corner (nasolacrimal duct) for one minute after instillation to reduce systemic absorption.

• Therapy should be continued as prescribed to maintain consistent intraocular pressure control.

Contraindications

Zolaren Suspension 1% is contraindicated in:

• Patients with known hypersensitivity to Brinzolamide, other sulfonamides, or any component of the formulation

• Individuals with severe renal impairment or significant kidney disease, as systemic absorption, though minimal, may increase risk

• Children under 2 years of age due to lack of established safety and efficacy

Side Effects

Common side effects are generally mild and ocular in nature, including:

• Eye discomfort, stinging, or burning upon instillation

• Blurred vision or transient visual disturbances

• Bitter or unusual taste in the mouth

• Conjunctival hyperemia or irritation

Rare systemic effects may include mild fatigue or headache. Most adverse reactions are dose-related and resolve with continued therapy or dosage adjustment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions & Warnings

• Use with caution in patients with mild to moderate kidney impairment or a history of sulfonamide allergy.

• Avoid contact lenses during administration if eye irritation develops.

• Regular monitoring of intraocular pressure is recommended to assess efficacy.

• Patients should inform their healthcare provider if they experience significant ocular pain, sudden vision changes, or signs of hypersensitivity.

Therapeutic Class

Ophthalmic Carbonic Anhydrase Inhibitor

Storage Conditions

Store Zolaren Suspension 1% in a cool, dry place, protected from light. Keep the container tightly closed and out of reach of children.